Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab premedication before first obinutuzumab infusion in previously untreated comorbid B-cell CLL
MOH_2017-06-05_000300Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Standard treatment plus tocilizumab with Standard treatment plus placebo (2 arms). Started Apr 2015; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2017-06-05_000300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-06-05_000300.